SEROXAT AND OTHER SSRIs

News and Views on the SSRI Group of Drugs

  • THE LIES ABOUT SEROXAT/PAXIL AND OTHER SSRIs

  • STOP the Lies: Join the Cause: Click pic below

  • Enter your email address to subscribe to this blog and receive notifications of new posts by email.

    Join 7 other followers

  • Monthly Archive showing # of posts

Another blow for GSK!!

Posted by shutah on May 6, 2007

 PharmaTimes 2 May 2007 – ADVAIR – “asthma blockbuster”

GlaxoSmithKline has not received the full backing it was hoping for from a US regulators’ panel to support its view that the highest dose of its asthma blockbuster Advair Diskus can increase survival rates for patients with chronic obstructive pulmonary disease.

This is a blow for GSK which had submitted data from three clinical trials to the FDA in support of the new indication for Advair, including the landmark study TORCH which involved over 6,110 patients. TORCH showed a 2.6% improvement in survival over three years among patients receiving Advair compared to placebo, but the FDA said that when looking at the USA alone, the survival benefit was 1.6%.

Advair is GSK’s best-selling drug, with first-quarter revenues reaching £835 million (+11%) and this figure would be boosted if expanded use were granted.  

Sounding at all familiar ??? 
 

Advertisements

One Response to “Another blow for GSK!!”

  1. Just imagine if GSK had presented the negative trial data to the FDA!

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

 
%d bloggers like this: